Nektar Therapeutics NKTR incurred a loss per share of 18 cents in the third quarter of 2024, narrower than the Zacks ...

The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its ...

DelveInsight's 'NK Cell Therapy Pipeline Insight 2024' report provides comprehensive global coverage of pipeline NK cell ...

Nektar Therapeutics (NKTR) extends its cash runway into 2026 with strategic divestitures, despite ongoing financial ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

Nektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers ...

SAN FRANCISCO — SAN FRANCISCO — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it had a loss ...

The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and ...